Health
RSV Drug Approved in US for Use in Infants
- Drug is first to fight dangerous virus for most babies
- RSV can be fatal, nearly all children get it before age two
RSV vaccine is poured into glass vials at a research and development center in Wavre, Belgium.
Photographer: Ksenia Kuleshova/BloombergThis article is for subscribers only.
AstraZeneca Plc and Sanofi’s drug for RSV in infants was approved in the US, the first-ever preventive intended for wide use against a common but dangerous virus in young children.
The green light from the Food and Drug Administration came ahead of the US RSV season, which normally picks up in the fall but has also surged in the spring and summer in recent years as the Covid-19 pandemic has shifted when viruses hit.